Fig 1: Inhibition of Notch4/Dll4 signaling decreases the expression of VEGF and its receptors in LPS-induced PMVECs. (A) The mRNA expression levels of Notch4 and Dll4 were determined by reverse transcription-quantitative PCR in PMVECs that were exposed to different concentrations of LPS. (B) Notch4, (C) Dll4, (D) VEGF, (E) Flt-1 and (F) Flk-1 mRNA levels were determined in PMVECs in the control, LPS and DAPT+LPS groups. (G) Western blot analysis of protein expression levels in the PMVEC treatment groups. Data are presented as the mean ± SD (n=6 per group). *P<0.05 with comparisons shown by lines. Dll4, delta-like canonical Notch ligand 4; PMVECs, pulmonary microvascular endothelial cells; LPS, lipopolysaccharide; Flt-1, FMS-like tyrosine kinase 1; Flk-1, fetal liver kinase 1.
Fig 2: Aberrant expression of Notch4, Dll4, NF-?B, VEGF, Flt-1 and Flk-1 in the rat lung after intrauterine infection. (A) The mRNA expression levels of Notch4, (B) Dll4, (C) NF-?B, (D) VEGF, (E) Flk-1 and (F) Flt-1 were evaluated in the two groups by reverse transcription-quantitative PCR. (G) The protein expression levels of Notch4, Dll4 and NF-?B, and (H) VEGF, Flt-1 and Flk-1 were determined in the two groups at P3 by western blotting. Data are presented as the mean ± SD (n=10 per group). *P<0.05. Dll4, delta-like canonical Notch ligand 4; Flt-1, FMS-like tyrosine kinase 1; Flk-1, fetal liver kinase 1; P, postnatal day.
Supplier Page from Abcam for Anti-VEGF Receptor 1 antibody [Y103] - Low endotoxin, Azide free